Johnson & Johnson faces possible criminal liability for the contaminated products, like Tylenol, coming from its division McNeil Consumer Healthcare.
William Weldon got the invitation to attend Thursday’s hearing with the House Committee on Oversight and Government Reform with some FDA officials but the J&J CEO did not commit due to his health issues.
Worldwide chairman for J&J, Colleen Goggins gave her testimonies pertaining to the recalls that severely marred J&J’s reputation as safe products especially for newborns. She has particularly spoken about the May 1 incident, which she claims is a precaution to the presence of “tiny particles” in the content which she assures to be non-hazardous. On top of that, Goggins also defended McNeil on issues showing that excess acetaminophen or bacteria can never pass through its quality inspection.
On the latest count, there are at least 775 grave side effects cases submitted to FDA involving McNeil products. Even 30 cases of death are blamed on these medicines. Johnson & Johnson has already suspended the production of the McNeil site but these complaints are already hunting them down.
Customers’ complaint began in 2008 but it was only in September of 2009 when McNeil started to recall several Tylenol items that are mostly for infants and children.
Related posts:
- FDA criticized Johnson & Johnson’s Tylenol plant
- McNeil and Johnson & Johnson under investigation
- Tylenol Recall 2010 by McNeil Consumer Healthcare